<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="shortcut icon" href="../figures/favicon.png" type="image/x-icon">
  <title>Pulmonary Tuberculosis and Pregnancy</title>
  <link href="https://cdn.jsdelivr.net/npm/remixicon@2.5.0/fonts/remixicon.css" rel="stylesheet">
  <link rel="stylesheet" href="/style.css">
  <link rel="stylesheet" href="/notes.css">
</head>
<body>
  <input type="checkbox" id="main-navigation-toggle" class="btn btn--close" title="Toggle main navigation" />
  <label for="main-navigation-toggle">
    <span></span>
  </label>
  
  <a href="/index.html">
    <div class="home-navigation">
      M
    </div>
  </a>

  <nav id="main-navigation" class="nav-main">
    <ul class="menu">
      <li class="menu__item">
        <a class="menu__link" href="/index.html">Home</a>
      </li>
      <li class="menu__item">
        <a class="menu__link" href="/about-temp2.html">About</a>
      </li>
      
     
      

      <li class="menu__item">
        <a class="menu__link" href="#0">Projects</a>
        <ul class="submenu">
          <li class="menu__item">
            <a class="menu__link" href="/404.html">Surgery</a>
          </li>
          <li class="menu__item">
            <a class="menu__link" href="/404.html">Pediatrics</a>
          </li>
        </ul>
      </li>
    </ul>
  </nav>
  
  <main class="page-container">
    <div class="contribute-cta">
      <p>Help make this betterðŸ’œ</p>
      <span><a href="/contribute.html">Contribute here</a> </span>
    </div>

    <h1>Pulmonary Tuberculosis and Pregnancy</h1>
  
    <!-- <div class="author-flex">
      <div class="author-img">
        <img  src="/contributors/vt1.jpeg" alt="">
      </div>
      <div>
        <h2 class="name">Compiled by Victortayo</h2>
        <p class="updated">last updated, Nov 2022</p>
      </div>
    </div> -->

    <article class="notes">
        <a id='top'></a>
    <article>
    <!-- <h2 class='title'>Outline</h2> -->
    <label class="trigger outline">
        <input type="checkbox" class="checkbox checkbox--red" /> Show/hide outline
        <div class="msg">
         <ol>
            <li><a href="#header-1">Introduction</a></li>
            <li><a href="#header-2">Epidemiology</a></li>
            <li><a href="#header-3">Pathology</a></li>
            <li><a href="#header-4">Effect of TB on pregnancy</a></li>
            <li><a href="#header-5">Effect of Pregnancy on TB</a></li>
            <li><a href="#header-6">Management of PTB in Pregnancy</a></li>
            <li><a href="#header-7">Breastfeeding</a></li>
            <li><a href="#header-8">Extrapulmonary TB</a></li>
            <li><a href="#header-9">Congenital Tuberculosis</a></li>
            <li><a href="#header-10">MDRTB & HIV Infection</a></li>
            <li><a href="#header-11">Conclusion</a></li>

         </ol>
        </div>
      </label>

      <section id='header-1'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-1'>Introduction</a>
          </h2>
        </header>
        <div class='body'>
            <p>Tuberculosis (TB) is caused by Mycobacterium tuberculosis, M bovis, or M. africanum</p>
            <p>These are slow-growing, aerobic, acid-fast bacilli, facultative intracellular organisms</p>
            <p>The most common presentation is pulmonary tuberculosis which is a lower respiratory tract infection</p>
            <p>TB is the leading infectious cause of mortality globally</p>
            <p>Active TB during pregnancy is associated with increased risk of poor maternal and fetal outcomes</p>
        </div>

      </section>

      <section id='header-2'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-2'>Epidemiology</a>
          </h2>
        </header>
        <div class='body'>
            <p>It is estimated that 1/3rd of the worldâ€™s population is infected with TB</p>
            <p>Only 5-10% will progress to active TB in their lifetime (difficult to predict)</p>
            <p>It is 20 â€“ 50 times commoner in developing countries</p>
            <p>TB is on the increase due to </p>
            <ul>
                <li>HIV</li>
                <li>Poor socioeconomic conditions</li>
                <li>Inadequate nutrition</li>
                <li>Overcrowding</li>
                <li>Antibiotics abuse</li>
                <li>Breakdown of health care systems</li>
                <li>Poorly supervised treatment</li>
                <li>Use of immunosuppressive drugs: e.g. steroids, cytotoxics</li>
                <li>Migration from regions of high endemicity</li>
            </ul>
            <p>Worldwide, about 3 million women become afflicted with TB per annum and 750,000 die</p>
            <p>TB is one of the leading infectious disease causes of death in women</p>
            <p>The global burden of TB in pregnancy is not well known</p>
            <p>Transmission is airborne from a contagious person</p>
            <p>Pulmonary TB is the most common manifestation in pregnancy</p>

        </div>
      </section>

      <section id='header-3'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-3'>Pathology</a>
          </h2>
        </header>
        <div class='body'>
            <h4><span class="special-text-4">Primary infection: </span></h4>
            <p>First infection with one of Mycobacterium tuberculosis complex â€“ most commonly M. tuberculosis. It is usually subpleural, often in the mid to upper lung zones (primary/Ghon focus)</p>
            <p>Within an hour of reaching the alveoli, tubercle bacilli reaches the draining lymph nodes at the hilum of the lungs and a few escape into the blood stream.</p>

            <h4><span class="special-text-4">Host response:</span></h4>
            <p>Initially infiltration with neutrophil granulocytes</p>
            <p>Rapidly replaced by alveolar macrophages which ingest the tubercle bacilli</p>
            <p>Interact with the T lymphocytes with development of cellular immunity (can be demonstrated 3-8 weeks by a positive tuberculin skin test) </p>
            <p>The bacilli evade death and multiply within these macrophages</p>
            <p>Delayed hypersensitivity type reaction occurs resulting in tissue necrosis (caseous necrosis) with at least 20% of these containing tubercle bacilli, initially lying dormant but capable of reactivation</p>

            <h4><span class="special-text-4">Possible fate of Primary infection</span></h4>
            <p><span class="special-text">Latent TB</span>: asymptomatic, non-infectious state after the host has mounted an effective granulomatous response.</p>
            <p><span class="special-text">Primary TB</span>: refers to active disease within the first two years of infection, symptomatic and infectious</p>
            <p><span class="special-text">Reactivation disease</span>: active disease after a period of latency beyond two years.</p>

        </div>
      </section>

      <section id='header-4'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-4'>Effects of TB on pregnancy</a>
          </h2>
        </header>
        <div class='body'>
            <p>Current opinion holds that pregnancy and TB do not affect each otherâ€™s course.</p>
            <p>However, active TB has adverse obstetrical and neonatal outcomes:</p>
            <ul>
                <li>Miscarriage</li>
                <li>Preterm labor	</li>
                <li>Low birth weight</li>
                <li>Antenatal admission	</li>
                <li>Anemia in pregnancy</li>
                <li>Preterm rupture of membranes</li>
                <li>IUGR</li>
                <li>Congenital tuberculosis (Rare)</li>
                <li>Prematurity</li>
            </ul>
        </div>
      </section>

      <section id='header-5'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-5'>Effects of pregnancy on TB</a>
          </h2>
        </header>
        <div class='body'>
            <p>Pregnancy does not appear to increase susceptibility to TB infection or progression from latent to active TB</p>
            <p>Pregnancy delays diagnosis of TB due to masking of symptoms and hesitancy in screening for TB as a differential</p>
        </div>
      </section>

      <section id='header-6'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-6'>Management of PTB in pregnancy</a>
          </h2>
        </header>
        <div class='body'>
           <p>Diagnosis requires a high index of suspicion</p>
           <p>Multidisciplinary: Obstetrician, pulmonologists, infectious unit, dietician, hematologists, microbiologists etc.</p>
           <ul>
            <li>History</li>
            <li>Examination</li>
            <li>Investigations</li>
            <li>Treatment</li>
           </ul>

           <section id='heading-6-1'>
            <header>
              <h3>
                <a aria-hidden href='#heading-6-1'>History</a>
              </h3>
            </header>
            <div class='body'>
               <ul>
                <li>Symptoms are non-specific and occur over weeks or months</li>
                <li>Chronic cough (>3 weeks), hemoptysis, anorexia, fever, malaise, weight loss, drenching night sweats, chest pain etc.  </li>
                <li>BCG vaccination status</li>
                <li>Past or present contact with infectious/active TB patients</li>
                <li>HIV status</li>
                <li>Other immunosuppressive states</li>
               </ul>
            </div>
           </section>

           <section id='heading-6-2'>
            <header>
              <h3>
                <a aria-hidden href='#heading-6-2'>Examination</a>
              </h3>
            </header>
            <div class='body'>
               <ul>
                <li>Also non-specific</li>
                <li>Can be normal</li>
                <li>Pneumonia</li>
                <li>Pleural effusion</li>
                <li>Pulmonary fibrosis</li>
               </ul>
            </div>
           </section>

           <section id='heading-6-3'>
            <header>
              <h3>
                <a aria-hidden href='#heading-6-3'>Investigations</a>
              </h3>
            </header>
            <div class='body'>
               <p><span class="special-text">Specific investigations</span>: sputum (AFB, culture and sensitivity), GeneXpert test (Nucleic acid amplification test)</p>
               <p><span class="special-text">Blood test</span>: interferon-gamma release assay</p>
               <p><span class="special-text">Radiological</span>: CXR</p>
               <p><span class="special-text">Non-specific investigations</span>: FBC, EUCr, Liver function tests, viral markers </p>
            </div>
           </section>

           <section id='heading-6-4'>
            <header>
              <h3>
                <a aria-hidden href='#heading-6-4'>Treatment</a>
              </h3>
            </header>
            <div class='body'>
               <p>Multidisciplinary</p>
               <p>Personal protective equipment</p>
               <p>Contact tracing</p>
               <p>Directly observed therapy (DOT) especially in active TB. This increases the likelihood of compliance, and decreases likelihood of multi-drug resistant TB. Health worker directly observe patients as they take their medications. </p>
               <p>Anti-Kochâ€™s treatment</p>

               <section id='heading-6-4-1'>
                <header>
                  <h4>
        
                    <a aria-hidden href='#heading-6-4-1'>Treatment of latent TB infection (LTBI)</a>
                  </h4>
                </header>
                <div class='body'>
                    <p>Pregnant women with LTBI are at high risk of developing active TB especially if HIV+ or had contact with active TB cases</p>
                    <p>Such women should begin treatment in the first trimester in the aforementioned</p>
                    <p>It is recommended (CDC and ACOG) that targeted screening should be done in high risk populations and treatment delayed until 2 â€“ 3 months postpartum except in HIV+ or recent TB infection</p>
                    <p>Isoniazid is considered safe for treatment of LTBI for 6 months</p>
                    <p>Pyridoxine (Vitamin B6) supplementation is required to diminish risk of peripheral neuropathy. </p>
        
                </div>
               </section>

               <section id='heading-6-4-2'>
                <header>
                  <h4>
        
                    <a aria-hidden href='#heading-6-4-2'>Treatment of active TB </a>
                  </h4>
                </header>
                <div class='body'>
                    <h4><span class="special-text-4">Intensive/Initial phase:</span></h4>
                    <ul>
                        <li>Intended to kill actively replicating bacteria.</li>
                        <li>It consists of four-drug plan; RIPE [Rifampicin (RIF), Isoniazid (INH), Pyrazinamide (PZA) and Ethambutol (EMB)]</li>
                        <li>Duration of use is 2 months</li>
                    </ul>

                    <h4><span class="special-text-4">Continuation phase:</span></h4>
                    <ul>
                        <li>Consists of Rifampicin and Isoniazid</li>
                        <li>Duration of use in 4 â€“ 7 months (mostly 6 months)</li>
                    </ul>
                    <p>The choice of drugs and duration of administration depend on organism susceptibility, site, severity of disease and protocol adopted by the region e.g. Pyrazinamide although recommended by the WHO is relatively contraindicated in USA except in extrapulmonary or severe active TB disease or HIV co-infection</p>
                    <p>If Pyrazinamide is not included in regimen, minimum duration of treatment is 9 months</p>
                    <p>Anti-Kochâ€™s regimen are safe throughout pregnancy</p>
                    <p>Anti-Kochâ€™s cross the placenta but only streptomycin has been documented to have teratogenic effects (Ototoxicity, congenital deafness)</p>
                    <p>Pyridoxine (25mg/day) should be given to pregnant women receiving Isoniazid</p>
                    <p>Isoniazid may be associated with increased risk of hepatotoxicity in pregnancy therefore monitoring with LFT is important</p>
                    <p>Rifampicin has been linked with bleeding due to hypoprothrombinemia in both mother and infants if used in the last few weeks of pregnancy. Therefore, Vit K is recommended for both the mother and infant</p>
        
                </div>
               </section>
            </div>
           </section>
        </div>
      </section>

      <section id='header-7'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-7'>Breastfeeding </a>
          </h2>
        </header>
        <div class='body'>
           <p>Breastfeeding may continue in women being treated for LTBI</p>
           <p>Mycobacterium tuberculosis does not enter breast milk</p>
           <p>Anti-Kochâ€™s cross breast milk but have not been found to produce toxicity in the newborn</p>
           <p>Mothers with active TB who may transmit the disease:</p>
           <ul>
            <li>Should not be in direct contact with the baby</li>
            <li>Can express breast milk to feed the baby except there is a tuberculous breast lesion/ulcer involving both breasts</li>
            <li>Infants should have chemoprophylaxis with INH and RIF for at least 3 months</li>
            <li>However, if mother is undergoing treatment and non-infectious, chemoprophylaxis is not required</li>
           </ul>

           <h4><span class="special-text-4">Mothers with Tuberculous Breast Lesion</span></h4>
           <p>Should not breastfeed from the affected breast until lesion heals</p>
           <p>Should express and discard breast milk from affected breast to maintain breast milk supply</p>
           <p>May resume direct breastfeeding from the affected breast when she is no longer considered infectious i.e. amelioration of signs and symptoms, has been on therapy for at least 2 weeks and repeat smear is negative</p>

           <figure>
            <img src="/figures/ptb (1).png" alt="">
            <figcaption>PTB in Pregnancy- mother unlikely to be infectious due to adequate treatment duration and response </figcaption>
           </figure>

           <figure>
            <img src="/figures/ptb (2).png" alt="">
            <figcaption> PTB in Pregnancy- mother likely to be infectious due to inadequate treatment duration and response </figcaption>
           </figure>

           <figure>
            <img src="/figures/ptb (3).png" alt="">
            <figcaption>Mother with extrapulmonary TB in pregnancy </figcaption>
           </figure>
        </div>
      </section>

      <section id='header-8'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-8'>Extrapulmonary TB </a>
          </h2>
        </header>
        <div class='body'>
           <p>Refers to TB in other parts of the body</p>
           <p>It is usually not infectious</p>
           <p>Most common sites are lymph nodes, bones, CNS (meninges, intracranial tuberculomas), urogenital tract</p>
        </div>
      </section>

      <section id='header-9'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-9'> Congenital Tuberculosis</a>
          </h2>
        </header>
        <div class='body'>
           <p>TB can be transmitted from mother with active TB disease to the fetus transplacentally through the bloodstream, lymphatics or amniotic fluid. Therefore, all infants should be evaluated for congenital TB</p>
           <p>Congenital TB may present in the early neonatal period with sepsis, bronchopneumonia, hepatosplenomegaly, poor feeding</p>
           <p>Although rare, it has a high mortality rate.</p>
           <p>Evaluation in suspected congenital TB include histologic and mycobacterial culture of the placenta in addition to neonatal evaluation </p>
        </div>
      </section>

      <section id='header-10'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-10'>MDRTB & HIV Infection</a>
          </h2>
        </header>
        <div class='body'>
           <p>Multidrug resistant TB is TB resistant to the two first line or most effective TB medications â€“ Rifampicin and Isoniazid</p>
           <p>It necessitates treatment using second line drugs for which there is limited clinical experience</p>
           <p>These second line drugs may be successfully used without significant harm to the mother and child and without requiring therapeutic abortion</p>
           <p>Any TB positive patient should be tested for concurrent HIV infection because HIV greatly increases risk of progression to active TB</p>
           <p>Pregnant women with HIV should be screened early in pregnancy for TB and evaluated</p>
           <p>Drug interactions between HIV and TB medications especially rifampicin complicates TB treatment during pregnancy</p>
           <p>Second line drugs:</p>
           <ul>
            <li>Fluoroquinolones</li>
            <li>Amikacin</li>
            <li>Cycloserine</li>
            <li>Clofazimine</li>
            <li>Meropenem/Imipenem</li>
            <li>etc.</li>
           </ul>
        </div>
      </section>

      <section id='header-11'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-11'>Conclusion </a>
          </h2>
        </header>
        <div class='body'>
           <p>TB remains an increasingly common infectious disease among pregnant women worldwide</p>
           <p>Diagnosis of TB in pregnancy is frequently delayed and a high index of suspicion is required to detect it</p>
           <p>Its management is multidisciplinary</p>
           <p>High index of suspicion is required in its diagnosis</p>
           <p>BCG is a live attenuated vaccine and contraindicated in pregnancy</p>
        </div>
      </section>


      </section>

      <div class="contact">
        <hr style="margin: 3rem 0;">

        <p>Send us a <a href="mailto:obgyn.materia@gmail.com"><span class="special-text-2">mail</span></a> at 
         <br> obgyn.materia@gmail.com.</p>
        <p>Or send your comments, corrections, explanations/clarifications and requests/suggestions to our 
         <br> <a href="" class="special-text-2" style="text-decoration: none;">WhatsApp group</a>.</p>
      </div>
    </article>
   </article>
   <div style="height: 300px;"></div>
  </main>

  <footer>
    <div class="footer-container">
        <div>
          <p>obgyn.materia</p>
          
        </div>
    </div>
  </footer>
<!------------  SCROLL UP ----------->
<a href="#" class="scrollup" id="scroll-up"> 
  <i class="ri-arrow-up-fill scrollup__icon"></i>
</a>
<script src="/main.js"></script>
</body>
</html>
 
